



News Release

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, +1-508-816-6730, rtrahan@ronaldtrahan.com

CardioMech Expands Mitral Leadership Team Company Elects New Directors, Board Advisor, and Appoints VP Finance on Heels of Recent \$2.5 Million Financing

OSLO, March 18, 2019 – [CardioMech AS](#), a privately held company developing a transcatheter mitral valve repair technology, today announced it has expanded its leadership team with the election of two new board directors – **Kathleen Tune** of [Fourth Element Capital](#), and **Frederik Groenewegen** of [415 CAPITAL](#), a board advisor, **Vic Bertrand** and appointed **Daniele Salamone** as Vice President of Finance.

The CardioMech device is a highly differentiated technology designed to significantly improve the standard of care for patients suffering from severe, symptomatic degenerative mitral regurgitation due to prolapse or flail. **“I am extremely pleased to announce this expansion of CardioMech’s mitral leadership team with the addition of four experienced medical technology professionals,”** said [Rick Nehm](#), **President and CEO of CardioMech**.

Kathleen is a proven healthcare executive with over 25 years of investing and business experience. She co-founded and manages a healthcare investment firm Fourth Element Capital and previously was a partner at the healthcare investment firm Thomas, McNerney & Partners. **“CardioMech is participating in one of the most innovative segments of medicine with a significant unmet need,”** said **Kathleen Tune**.

Frederik, co-founder and managing director of 415 CAPITAL, a designated medical technology investment firm whose senior team has backed over 45 novel medical device technologies, including CoreValve ([Medtronic](#)), CardiAQ ([Edwards Lifesciences](#)), and Claret ([Boston Scientific](#)). Frederik brings extensive fundraising, M&A and commercialization experience to the CardioMech team. **“Transcatheter mitral valve repair is a hot market segment, and we believe CardioMech is strongly positioned for a leadership role in chordal repair,”** said **Frederik Groenewegen**.

Vic, a veteran medical technology investor and director who was appointed as a CardioMech Advisor, is also an entrepreneur with 30 years’ experience in medical technology, manufacturing, and real estate, said, **“I am thrilled to support Rick and the CardioMech team on their mission to bring this innovative and much needed solution to the affected population globally,”** said [Vic Bertrand](#).

[Daniele Salamone](#), CardioMech’s new Vice President of Finance, brings tremendous experience to the company to accelerate and guide the creation of shareholder value. He is an experienced strategy consultant with expertise in corporate development, strategic planning, and M&A transactions. His background is in innovation with startups and corporate innovation initiatives. He has direct experience with structural heart device commercialization. He was most recently at The Boston Consulting Group.

Caution: The CardioMech device is in the early R&D development phase and is NOT approved or cleared by the FDA or any other regulatory body in any region of the world.

-END-